Aileron Therapeutics, Inc.

    Aileron Therapeutics, Inc.

    NNASDAQ:ALRN
    2.05
    USD
    -0.25
    (-10.87%)
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    TTM
    Revenue per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Basic EPS, GAAP
    -23.6
    -33.35
    -60.74
    -42.81
    -23.94
    -12.14
    -5.89
    -6.02
    -3.42
    -1.76
    Free Cash Flow per Basic Share
    -21.63
    -27.51
    -55.55
    -43.9
    -21.7
    -11.75
    -5.38
    -5.48
    -4.31
    -1.68
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    -176.32
    -209.53
    -367.94
    -228.63
    -161.49
    -125.76
    -55.26
    -60.07
    -62.72
    -18.66
    Tangible Book Value per Share
    -172.83
    -204.88
    128.43
    26.6
    13.08
    6.98
    9.89
    4.1
    -17.1
    -2.12
    Basic Weighted Avg Shares
    1
    1
    - -
    1
    1
    2
    4
    5
    5
    17
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Net Income, GAAP
    -13
    -18
    -23
    -32
    -29
    -21
    -26
    -27
    -16
    -29
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Working Capital
    1
    17
    47
    16
    14
    12
    44
    18
    14
    13
    LT Debt
    - -
    - -
    - -
    5
    5
    - -
    - -
    - -
    - -
    - -
    Total Equity
    -94
    -112
    48
    20
    16
    12
    44
    19
    7
    50
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    17
    22
    22
    Market Capitalization
    38
    30
    59

    Working Capital

    USD

    •

    in mil. unless spec.
    Mar'24
    Jun'24
    Sep'24
    Total Current Assets
    13
    23
    19
    Cash, Cash Equivalents & STI
    12
    22
    18
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    5
    5
    6
    Payables & Accruals
    4
    5
    6
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    - -
    19.61%
    -63.02%
    Free Cash Flow
    - -
    -8.07%
    -20.34%
    Net Income, GAAP
    - -
    -9.83%
    -42.43%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -1.86
    -1.76
    -1.4
    - -
    -6.02
    2023
    -1.05
    -0.39
    -0.4
    - -
    -3.42
    2024
    -0.86
    -0.45
    -0.27
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • prnewswire.com

      Aileron Therapeutics Announces Rebranding to Rein Therapeutics

    • prnewswire.com

      Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

    • prnewswire.com

      Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

    • prnewswire.com

      Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma

    • prnewswire.com

      Aileron Therapeutics to Present Previously Announced Data from the Phase 1b Clinical Trial Evaluating Low-Dose LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) at the 22nd International Colloquium on Lung and Airway Fibrosis

    • prnewswire.com

      Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

    • prnewswire.com

      Aileron Therapeutics to Present at the 8th Annual IPF Summit

    • prnewswire.com

      Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

    • prnewswire.com

      Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

    • prnewswire.com

      Aileron Therapeutics to be Included in the Russell Microcap® Index

    • globenewswire.com

      Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

    • zacks.com

      Down -36.29% in 4 Weeks, Here's Why Aileron Therapeutics (ALRN) Looks Ripe for a Turnaround

    • globenewswire.com

      Aileron Therapeutics to Present at Two Upcoming Investor Conferences

    • globenewswire.com

      Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million

    • globenewswire.com

      Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million

    • globenewswire.com

      Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

    • globenewswire.com

      Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    • globenewswire.com

      Aileron Therapeutics Announces CEO Transition

    • globenewswire.com

      Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event

    • globenewswire.com

      Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024